OrthoPediatrics to report Q2 2026 financial results on August 4

0 min read Updated on 22 Jul 2026, 05:50 AM

Reviewed by

Naman SScanX News Team

AI Summary

OrthoPediatrics Corp. will announce its Q2 2026 financial results on August 4, 2026, followed by a conference call at 4:30 p.m. ET. The company specializes in pediatric orthopedics, offering over 90 systems across trauma, deformity, scoliosis, and sports medicine. Investors can access the webcast replay on the company's website for 90 days.

*this image is generated using AI for illustrative purposes only.

OrthoPediatrics Corp. will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market closes. The company, focused exclusively on advancing the field of pediatric orthopedics, will host a conference call at 4:30 p.m. ET on the same day to discuss the results. Investors can access the live and archived webcast on the Investors page in the Events & Presentations section of the company's website. The webcast will be available for replay for at least 90 days after the event.

OrthoPediatrics markets over 90 systems serving three of the largest categories within the pediatric orthopedic market: trauma and deformity, scoliosis, and sports medicine/other procedures. The company's global sales organization distributes its products in the United States and over 75 countries outside the United States. Founded in 2006, OrthoPediatrics aims to improve the lives of children with orthopedic conditions through its comprehensive product offering.

For more information about OrthoPediatrics Corp., visit www.orthopediatrics.com . Details about the OrthoPediatrics Specialty Bracing portfolio are available at www.opsb.com .

What key performance indicators will investors focus on during the Q2 2026 earnings call?

How might OrthoPediatrics' international expansion impact its revenue growth in the coming quarters?

What new product launches or innovations could drive growth in the pediatric orthopedics market?

Rating and Price Target Details

The research note from Truist Securities updates the investment thesis on OrthoPediatrics, keeping the recommendation at Hold. The price target increase signals a potential upside from current levels, though the stock remains categorized as a hold rather than a buy.